In vitro and in vivo rationale for the triple combination of panobinostat (LBH589) and dexamethasone with either bortezomib or lenalidomide in multiple myeloma

BACKGROUND: Combinations of drug treatments based on bortezomib or lenalidomide plus steroids have resulted in very high response rates in multiple myeloma. However, most patients still relapse, indicating the need for novel combination partners to increase duration of response or to treat relapsed...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
Main Authors: Ocio, Enrique M., Vilanova, David, Atadja, Peter, Maiso, Patricia, Crusoe, Edvan, Fernández-Lázaro, Diego, Garayoa, Mercedes, San-Segundo, Laura, Hernández-Iglesias, Teresa, de Álava, Enrique, Shao, Wenlin, Yao, Yung-Mae, Pandiella, Atanasio, San-Miguel, Jesús F.
Format: Artigo
Jezik:Inglês
Izdano: Ferrata Storti Foundation 2010
Teme:
Original Article
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC2864386/
https://ncbi.nlm.nih.gov/pubmed/19951978
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3324/haematol.2009.015495
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki